Table 3.
Mortality and short-term outcomes comparison between classic and inSurE method or classic and LISA method.
| Variables | Classic method (n = 2,181) | InSurE method (n = 295) | LISA method (n = 191) | ||||
|---|---|---|---|---|---|---|---|
| Applicable/enrolled patient n (%) | Applicable/enrolled patient n (%) | AORa (95% CI) |
p-value | Applicable/enrolled patient n (%) | AORa (95% CI) |
p-value | |
| Mortality | 390/2,181 (17.9) | 6/295 (2.0) | 0.377 (0.146–0.978) | 0.045* | 4/191 (2.1) | 0.296 (0.102–0.862) | 0.026* |
| BPD, ≥ moderate | 874/1,761 (49.6) | 61/291 (21.0) | 0.691 (0.479–0.998) | 0.049* | 51/187 (27.3) | 0.544 (0.355–0.831) | 0.005* |
| IVH grade ≥ grade Ⅱ | 510/2,085 (24.5) | 14/294 (4.8) | 0.524 (0.287–0.956) | 0.035* | 16/191 (8.4) | 0.837 (0.473–1.481) | 0.541 |
| PH | 160/2,021 (7.9) | 9/295 (3.1) | 0.937 (0.428–2.051) | 0.870 | 5/191 (2.6) | 0.473 (0.164–1.365) | 0.166 |
| PHN | 376/2,181 (17.2) | 7/295 (2.4) | 0.350 (0.150–0.817) | 0.015* | 7/191 (3.7) | 0.276 (0.107–0.713) | 0.008* |
| Air leak syndrome | 130/2,181 (6.0) | 5/295 (1.7) | 0.679 (0.262–1.764) | 0.427 | 6/191 (3.1) | 1.062 (0.431–2.618) | 0.895 |
| NEC ≥ grade Ⅱ | 174/2,181 (8.0) | 12/295 (4.1) | 1.015 (0.526–1.959) | 0.964 | 14/191 (7.3) | 1.234 (0.641–2.373) | 0.529 |
| Sepsis | 477/2,181 (21.9) | 45/295 (15.3) | 1.328 (0.900–1.959) | 0.153 | 31/191 (16.2) | 0.858 (0.536–1.373) | 0.523 |
| PVL | 220/2,084 (10.6) | 9/294 (3.1) | 0.382 (0.187–0.780) | 0.008* | 5/191 (2.6) | 0.246 (0.096–0.627) | 0.003* |
| ROP with treatment | 267/2,181 (12.2) | 6/295 (2.0) | 0.544 (0.229–1.295) | 0.169 | 12/191 (6.3) | 0.937 (0.454–1.932) | 0.859 |
| PDA with treatment | 887/2,181 (40.7) | 78/295 (26.4) | 0.628 (0.454–0.868) | 0.005* | 41/191 (21.5) | 0.467 (0.313–0.696) | <0.001* |
A multivariate binary logistic regression model was used and the Classic method was the reference group.
AOR, adjusted odds ratio; CI, confidence interval; InSurE, Intubation-Surfactant-Extubation; LISA, less invasive surfactant administration; BPD, Bronchopulmonary dysplasia; IVH, Intraventricular hemorrhage; PH, pulmonary hemorrhage; PHN, pulmonary hypertension; NEC, necrotizing enterocolitis; PVL, periventricular leucomalacia; ROP, retinopathy of prematurity; PDA, patent ductus arteriosus.
Odds ratios and p-values adjusted for clinical characteristics and perinatal risk factors that significantly differed among the three surfactant replacement therapy groups.
p-value < 0.05.